Uniquely, the AlzyFinder Platform is the first of its kind to be offered openly to the community, encapsulating machine learning models that have been rigorously tested and validated through different methodologies for virtual screening. AlzyFinder Platform aims to bridge this gap in AD drug design by providing a comprehensive tool for multitarget ligand identification. This unique free web-based tool not only predicts interactions of candidate molecules with essential targets but also, from a systems pharmacology view, allows to identify potential multitarget ligands, and to unravel the systemic actions of these ligands mediating their therapeutic effects in Alzheimer's disease. AlzyFinder Platform is freely accessible at , where users can explore its functionalities. Additionally, and all the models, as well as the scripts and other required specifications to use this platform in standalone format are available in the AlzyFinder GitHub repository available at .